Comparing the current results to its competitors, Spero Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.07 %, recorded in the same quarter.
Spero Therapeutics Inc , slower than the average decrease reported by the company's competitors of -58.63 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -58.63 %
October 2, 2024
Spero Therapeutics Announces Significant Progress in Antibacterial Treatment with SPR720: Phase 1 Data Published in Antimicrobial Agents and ChemotherapySpero Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, has made significant strides in its quest for effective therapies against multidrug-resistant pathogens. The company recently announced the publication of vital data from its Phase 1 clinical study of SPR720, an investigational treatment designed to combat infections caused by Mycobacterium tuberculosis (M. tuberculosis). Overview of SPR720 and its Mechanism of ActionSPR720, which is a prodrug, is converted in the body to its activ...
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative drugs. Their business model revolves around identifying potential drug targets, conducting research and preclinical studies to validate these targets, and subsequently developing drugs through clinical trials for various therapeutic areas. They also collaborate with pharmaceutical companies for joint development and commercialization efforts, aiming to bring these drugs to market and improve patient outcomes.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Spero Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Spero Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
